RayzeBio inc (DELISTED) (RYZB:DL)
62.49
0.00 (0.00%)
USD |
NASDAQ |
Mar 06, 16:00
Price Chart
Key Stats
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
RayzeBio inc is a company operating as vertically integrated radiopharmaceutical therapeutics company. The main objective of the company is defeating cancer with radiopharmaceutical medicines. It has a created a pipeline of multiple drug candidates, in therapeutic areas with significant market opportunities. They have a portfolio of potential RPT drug and development candidates that includes late-stage clinical programs, development programs and discovery programs. |
URL | https://www.rayzebio.com |
Investor Relations URL | https://investors.rayzebio.com/ |
HQ State/Province | California |
Sector | |
Industry | |
Equity Style | N/A |
Next Earnings Release | May. 31, 2024 (est.) |
Last Earnings Release | N/A |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
RayzeBio inc is a company operating as vertically integrated radiopharmaceutical therapeutics company. The main objective of the company is defeating cancer with radiopharmaceutical medicines. It has a created a pipeline of multiple drug candidates, in therapeutic areas with significant market opportunities. They have a portfolio of potential RPT drug and development candidates that includes late-stage clinical programs, development programs and discovery programs. |
URL | https://www.rayzebio.com |
Investor Relations URL | https://investors.rayzebio.com/ |
HQ State/Province | California |
Sector | |
Industry | |
Equity Style | N/A |
Next Earnings Release | May. 31, 2024 (est.) |
Last Earnings Release | N/A |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |